Mode
Text Size
Log in / Sign up

Insulin dose reduction during exercise yields similar glucose effects with ultra-rapid and rapid aspart

Insulin dose reduction during exercise yields similar glucose effects with ultra-rapid and rapid asp…
Photo by Hush Naidoo Jade Photography / Unsplash
Key Takeaway
Consider that insulin dose reduction magnitude may matter more than insulin type for exercise glucose management in T1D.

A randomized controlled trial in 43 adults with type 1 diabetes compared ultra-rapid-acting insulin aspart (URA-IAsp) to rapid-acting insulin aspart (IAsp) during laboratory-controlled moderate-intensity exercise. Participants received either insulin type at 50% or 75% reduced doses before exercise, with blood glucose and insulin concentrations monitored for 4 hours after the second insulin injection.

During exercise, blood glucose declined similarly across conditions: -4.0 ± 2.8 mmol/L with 50% dose URA-IAsp, -5.1 ± 3.0 mmol/L with 50% dose IAsp, -2.8 ± 3.3 mmol/L with 75% dose URA-IAsp, and -3.4 ± 3.3 mmol/L with 75% dose IAsp. The comparison between 50% dose URA-IAsp and all other conditions showed no significant difference (all p > 0.05). However, the 50% IAsp dose produced significantly greater glucose decline than both 75% reduced dose conditions (p < 0.05). Insulin concentrations differed only by dose amount, not insulin type, from 30 minutes after the first injection.

Safety and tolerability data were not reported. The study was conducted under specific laboratory conditions with a standardized exercise protocol, limiting generalizability to different exercise types, intensities, or durations. Clinical outcomes like hypoglycemia events and patient-reported outcomes were not assessed. While the RCT design supports causal inference for the tested interventions under study conditions, these findings represent preliminary evidence from a single controlled trial. The results suggest that insulin dose reduction magnitude may be more important than insulin type for managing glycemia during moderate exercise in type 1 diabetes, but real-world applicability requires further investigation.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
AIMS: To compare the effects of dose reductions of ultra-rapid-acting insulin aspart (URA-IAsp) and rapid-acting insulin aspart (IAsp) on blood glucose concentrations during continuous moderate-intensity exercise in people with type 1 diabetes (T1D). MATERIALS AND METHODS: In this double-blind, laboratory-controlled study, 43 adults with T1D completed four experimental visits in a randomised crossover design. Participants injected a 50% or 75% reduced dose of URA-IAsp or IAsp with a standardised breakfast 60 min prior to 45 min of cycling at ~61% V̇O. The same insulin type and dose were administered 4 h after the first injection, alongside an identical lunch meal. Venous blood samples were taken at 5-, 10-, and 15-min epochs, for a total of 70 timepoints, throughout the trial day until 4 h after the second injection to determine blood glucose and insulin concentrations. The primary endpoint was the four-way comparison of blood glucose change from exercise start to end. RESULTS: Blood glucose declined during exercise to a similar extent between 50% dose URA-IAsp (-4.0 ± 2.8 mmol L) and all other conditions (all p > 0.05), yet fell more in the 50% IAsp dose (-5.1 ± 3.0 mmol L) compared to the URA-IAsp (-2.8 ± 3.3 mmol L) and IAsp (-3.4 ± 3.3 mmol L) 75% reduced dose conditions (both p < 0.05). Differences in blood insulin concentrations between trials were only resultant of insulin doses and not insulin type from 30 min after the first insulin injection. CONCLUSIONS: Insulin dose reductions around acute moderate-intensity exercise yield similar glucose-lowering effects with URA-IAsp and IAsp. The extent of dose reductions exerts greater influence on glycaemia than the type of fast-acting insulin.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.